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To evaluate the ability of pretreatment liver stiffness measurements (pLSM) to predict hepa-
tocellular carcinoma (HCC), incident decompensation and all-cause mortality in chronic
hepatitis C (CHC) patients who achieved sustained virological response (SVR) after treat-
ment with direct-acting antivirals (DAAs).
Methods
773 CHC patients with SVR after DAA treatment and no prior liver complications were identi-
fied retrospectively. Optimized cut-off of 17.5 kPa for incident HCC was selected by maxi-
mum Youden’s index. Patients were grouped by pLSM: <10 kPa [reference], 10–17.4 kPa
and�17.5 kPa. Primary outcomes were incident hepatocellular carcinoma and secondary
outcomes were incident decompensated cirrhosis and all-cause mortality, analyzed using
cox-regression.
Results
Median follow-up was 36 months and 43.5% (336) had cirrhosis (LSM>12.5 kPa). The
median pLSM was 11.6 kPa (IQR 6.7–17.8, range 2.5–75) and pLSM of <10 kPa, 10–17.4
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kPa and 17.5–75 kPa was seen in 41.5%, 32.2% and 26.3%. During a median follow-up
time of 36 months, 11 (1.4%) developed HCC, 14 (1.5%) developed decompensated cirrho-
sis, and 38 (4.9%) patients died. A pLSM of 17.5 kPa identified patients with a high risk of
HCC with a negative predictive value of 98.9% and incidence rate of HCC in the 17.5–75
kPa group of 1.40/100 person years compared to 0.14/100 person years and 0.12/100 per-
son years in the 10–17.4 kPa and <10 kPa groups, p<0.001.
Conclusion
Pretreatment LSM predicts risk of HCC, decompensation and all-cause mortality in patients
with SVR after DAA treatment. Patients with a pLSM <17.5 kPa and no other risk factors for
chronic liver disease appear not to benefit from HCC surveillance for the first 3 years after
treatment. Longer follow-up is needed to clarify if they can be safely excluded from post
treatment HCC screening hereafter.
Introduction
Treatment with direct acting antivirals (DAAs) has been shown to decrease mortality and liver
related complications in patients with chronic hepatitis C (CHC) [1–7]. Current guidelines state
that patients with advanced fibrosis/cirrhosis (Metavir F3-4) need continued post-treatment
surveillance for hepatocellular carcinoma (HCC) every six months [8]. Given the huge number
of patients with advanced fibrosis and cirrhosis who will be cured with DAAs in the coming
years, it is a major research priority to identify patients who do not need to enter surveillance
for liver related complications after cure [9]. People cured for hepatitis C might have other
health issues and/or competing priorities that can make adherence to surveillance challenging.
This is especially an issue in marginalized populations such as people who inject drugs, but lim-
iting redundant procedures should be a priority for the health system at large [10].
A liver stiffness measurement (LSM) using vibration-controlled transient elastography
(VCTE) is currently being used to identify patients with advanced liver disease and has been
able to predict the prognosis of patients with chronic hepatitis [11–14]. Recently it has also
been shown to be useful in predicting outcome in patients treated with CHC treated with
DAAs [15–19], but most studies have focused on cirrhotic patients. Using LSM as a predicting
marker allows for less contacts with health care providers before treatment initiation, as com-
pared to biomarkers. This can be advantageous in outreach programs among marginalized
populations, such as homeless people and people who inject drugs (PWID).
The primary aim of this study was to evaluate the ability of pretreatment LSM (pLSM) to
predict incident decompensated cirrhosis and HCC and all-cause mortality in a cohort of
patients treated with DAAs. The secondary aims were to evaluate the prognostic ability of post
treatment LSM dynamics.
Material and methods
This study was approved by the Danish Patient Safety Authority (j. nr. 3-3013-2307/1) and the
Danish Data Protection Agency (j. nr. 17/29317).
Setting
Denmark has a population of 5.8 million people [20] and a HCV prevalence of 0.4% [21].
Patients with HCV infection are treated by infectious disease specialists or hepatologists in
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inpatient- or outpatient clinics. Medical care is provided free-of-charge; including treatment
with DAAs. The indication for DAA treatment in Denmark has been conservative: until Feb-
ruary 2017 LSM>12 kilopascal (kPa), hereafter it was decreased to>10 kPa and from Novem-
ber 2018, treatment has been offered regardless of liver fibrosis.
Data sources
We used the unique 10-digit registration number (PIN) assigned to all Danish citizens to link
individual level data from the following sources.
The Danish Database for Hepatitis B and C (DANHEP)
We identified patients with CHC and chronic hepatitis B in the Danish Database for Chronic
Hepatitis B and C (DANHEP) which is a nationwide database including all patients referred to
hospital for chronic hepatitis B and C in Denmark [22].
Liver stiffness measurements
The LSM were extracted directly from the Fibroscan software from centers that report to
DANHEP. Only valid procedures with at least 10 validated measurements and an interquartile
range (IQR) <30% in LSM�7.1 kPa were used in the study [23].
The Danish Civil Registration System (CRS)
The CRS was established in 1968 and contains daily updated information on the vital status of
all Danish citizens [24].
The Danish National Patient Register (DNPR)
The DNPR, established in 1977, records all hospital admissions to non-psychiatric hospitals in
Denmark. Data from outpatient clinics and emergency departments started in 1995. Records
for each medical contact includes the dates of admission and discharge and up to 20 discharge
diagnoses, coded according to the International Classification of Diseases, 10th revision from
1994 and onwards [25].
We used DNPR to identify heavy alcohol use, human immunodeficiency virus (HIV) status,
intravenous drug use, diabetes, decompensated cirrhosis and HCC.
Danish Registry of Causes of Death (DRCD)
DRCD contains information from all Danish death certificates issued since 1943. Computer-
ized and validated registry information is currently available through 2017. Whenever a Dan-
ish resident dies, the attending physician must report the cause of death. Causes of death
recorded during the study period were coded using ICD-10.
The Registry of Drug Users Undergoing Treatment (RDT)
The RDT is run by the National Board of Health in Denmark and registers all individuals
receiving treatment for drug addiction since 1996. It contains information on main drugs
used, route of administration and whether a patient receives opioid substitution treatment or
not [26].
We used the RDT to ascertain intravenous drug use (IDU).
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The Danish Cancer Registry (DCR)
The DCR contains records of all incidences of malignant neoplasms in the Danish population
since 1943 [27]. It is divided into personal characteristics at date of diagnosis and tumor char-
acteristics. We used DCR to ascertain HCC.
The Danish Pathology Register (DPR)
The DPR contains electronic registration of all pathological specimens since 1997, when it
became a legal obligation for all departments of pathology in Denmark to report to the
national board of health [28]. The information consists mainly of patient data and pathology
diagnoses using a Danish version of the Systematized Nomenclature of Medicine (SNOMED).
The DPR was used to ascertain HCC.
The Danish National Prescription Registry (DNPR)
The DNPR contains data on all dispensed prescriptions from Danish community pharmacies
since 1994 [29]. It was used to ascertain heavy alcohol use.
National Registry of Alcohol Treatment (NRAT)
The NRAT contains information on all public as well as private treatment for heavy alcohol
consumption since 1996 [30]. Data includes information on current treatment, previous treat-
ment, age of first alcohol ingestion and reasons for stopping treatment. The NRAT was used to
ascertain heavy alcohol use.
Study population
To be eligible for the study, patients identified as having CHC in DANHEP had to meet the
following criteria: (a) age 18 years or older at inclusion, (b) a positive test for HCV antibodies
and a concurrent or later positive HCV RNA (c) sustained virological response (SVR) post
treatment with DAAs, defined as HCV RNA result below the lower limit of quantification at
least 12 weeks after the end of treatment (d) a valid LSM < 2 years before initiation of treat-
ment with DAA (e) no coinfection with hepatitis B virus (HBV) or HIV (f) no episode of
decompensated cirrhosis or HCC prior to inclusion (g) no liver transplant prior to inclusion
(h) no HCC diagnosis <180 days after index date, in order to only include patients with inci-
dent HCC after treatment initiation.
The study included all patients fulfilling these criteria from 25. July 2012 until 24. May
2019. The index date was at the time of treatment initiation with DAAs and patients were fol-
lowed until death, immigration or 24. May 2019, whichever came first.
Definition of specific diagnoses
The definitions of diagnoses in the form of heavy alcohol use, hepatitis B, HIV, IDU, diabetes,
HCC, decompensated cirrhosis and western origin are shown in S1 Appendix.
Prognostic categories
We used cut-offs of pLSM of 10 in our study to define patients in the reference group. A cut-
off of 10 kPa is used to define severe fibrosis (F3) in patients with CHC, thereby identifying
patients who need continued post-treatment surveillance for HCC every six months [8] and
patients with a LSM < 10 kPa, were used as the reference group. The optimized cut-off using
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Youden’s index for predicting incident HCC after treatment in our cohort was used for com-
parison. Cirrhosis was defined as having a LSM >12.5 kPa [8].
In patients with repeated LSM, performed at least 90 days after treatment initiation, we cal-
culated the delta LSM (dLSM), defined as the difference in kPa between the last post treatment
LSM and the pLSM. The dLSM was reported as�0 or <0. For in whom the last post treatment
LSM was <10 kPa, dLSM was reported as<0 to avoid categorizing insignificant fluctuations
in LSM as possible fibrosis progression.
Outcomes
The primary outcome was incident HCC and secondary outcomes were incident decompen-
sated cirrhosis and all-cause death.
Statistical analysis
Person-years at risk were computed from the index date until the date of event, emigration, or
24. May 2019, whichever came first.
The significance level was set at a p-value < 0.05. Proportions and medians were compared
using Pearsons Chi2 and Kruskal-Wallis median test.
The cut-offs for optimized sensitivity and specificity, 90% sensitivity and specificity and
positive predictive value (PPV) and negative predictive value (NPV) was found by ROC analy-
sis and used in subsequent analyses, together with cut-off of 10 kPa and 12.5 kPa.
We computed incidence rates for all-cause mortality, HCC and decompensated cirrhosis
with 95% confidence intervals (CI). Kaplan-Meier survival curves were compared using log-
rank test. Cox regression was used to estimate hazard ratios for all-cause death. Competing
risk regression was used to estimate subhazard ratios for HCC and decompensated cirrhosis,
as death was a substantial competing risk for these two outcomes. The models included vari-
ables selected a priori of age, sex, Western European origin, diabetes, history of heavy alcohol
use and intravenous drug use (IDU) and pLSM. Delta LSM was included in the univariate
analysis but was omitted from multivariate analysis because of too few outcomes among
patients with a follow-up LSM. Predictors that were associated with the outcomes with a p-
value <0.0.05 were entered in a multivariate analysis.
All analyses were performed using STATA 15 IC software (Statacorp LP, College Station,
TX).
Results
Out of 1,763 patients evaluated for inclusion, 773 were included in the study (Fig 1).
The clinical characteristics of the study cohort are shown in Table 1.
Overall, the median age was 54 years (IQR 45–61, range 18–83), 63.7% were male and
84.2% were of Western origin. Diabetes was found in 10.5%, 51.2% had a registration of heavy
alcohol use and 63.1% had ever injected drugs.
The median pLSM was 11.6 kPa (IQR 6.7–17.8, range 2.5–75) and using the optimized cut-
off for incident HCC of 17.5 kPa (Fig 2), a pLSM of<10 kPa, 10–17.4 kPa and 17.5–75 kPa was
seen in 41.5%, 32.2% and 26.3, respectively. Cirrhosis, defined as a pLSM>12.5 kPa, was seen in
336 patients (43.5%). In 98.3% (760/773) at least one LSM had been performed before the pLSM.
Compared to patients with a pLSM < 10 kPa, patients with a pLSM�17.5 kPa were older
(56 years (IQR 49–61) vs 50 years (IQR 42–60), p<0.001), were more likely to be male (67.0%
vs 57.6%, p = 0.013), have a diagnosis of diabetes (17.2% vs 4.4%, p<0.001) or have a registra-
tion of heavy alcohol use (62.1% vs 43.9% p<0.001). Genotype (GT) 1 was found in 52.3%
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(348/666) and GT 3 in 39.2% (261/666) with 22.7% of patients with GT 1 having a pLSM
�17.5 kPa, compared to 24.9% of patients with GT 3 (p = 0.527).
The median follow-up period was 36 months (IQR 24–47, range 6–82) and the median
time from performance of pLSM to treatment initiation was 49 days (IQR 5–154).
Follow-up liver stiffness measurements
Among 467 patients with at least one follow-up LSM, the median time from treatment initiation
to last LSM was 35 months (IQR 20–53) and the median follow-up was 41 months (IQR 30–49).
Patients with a follow-up LSM were older than patients without a follow-up LSM (median
age 55 vs 52 years, p = 0.019) and had a higher pLSM (12.4 vs 9.9 kPa, p<0.001) but there was
no difference in sex, prevalence of diabetes, heavy alcohol use or IDU among the two groups.
Fig 1. Flow chart for inclusion. Abbreviations: DAA; direct-acting antivirals, CHC; chronic hepatitis C, LSM; liver stiffness measurement, HBV; hepatitis B
virus, HIV; human immunodeficiency virus, PY; person-years, EOF; end of follow-up. � First episode.
https://doi.org/10.1371/journal.pone.0243725.g001
PLOS ONE Incidence of HCC in chronic hepatitis C patients who achieve SVR following DAAs
PLOS ONE | https://doi.org/10.1371/journal.pone.0243725 December 10, 2020 6 / 17
Only 6.2% (29/467) of patients with�1 follow-up LSM had dLSM�0, while the majority
(93.8) had a dLSM <0.
For patients without a follow-up LSM, the median pLSM was 9.9 kPa (IQR 6.0–17.1) com-
pared to 12.4 kPa (IQR 7.4–18.8) among patients with a follow-up LSM. Among these, the
median pLSM was 15.4 kPa (IQR 10.4–23.7) for patients with a dLSM�0 compared to 12.2
kPa (IQR 7.1–18) among those with a dLSM <0.
A dLSM�0 was significantly associated with incident decompensated cirrhosis (6.9% (2/
29) vs 1.4% (6/438), p = 0.026) but not with HCC (3.5% (1/29) vs 1.8% (8/438), p = 0.538) or
al-cause mortality (3.5% (1/29) vs 4.1% (18/438), p = 0.861).
Hepatocellular carcinoma
Eleven (1.4%) patients developed HCC during the follow-up with an overall rate of HCC of
0.5/100 PY (95% CI 0.3–0.9/100 PY). The median follow-up for patients who developed HCC
was 22.8 months (IQR 7.6–29.2) and the median pLSM was 27.0 kPa (IQR 17.5–45.0, range
4.7–69.1).
The median age at diagnosis was 60 years (IQR 59–63, range 53–69).
The optimized cut-off for incident HCC was 17.5 kPa which identified 9/11 of patients with
incident HCC and had a sensitivity of 81.8% and specificity of 74.5% and a positive predictive
value (PPV) and negative predictive value (NPV) of 4.4% and 99.7%, respectively (Table 2).
There was no significant difference in HCC incidence rate between patients with a pLSM
<10 kPa and patients with a pLSM of 10–17.4 kPa (1/321 (0.31%), 0.12/100 PY vs 1/249
(0.4%), 0.14/100 PY, p = 0.925) but the HCC rate was significantly higher among patients with
a pLSM�17.5 kPa (9/203 (4.43%), 1.40/100 PY, p = 0.017) (Table 3, Fig 2).
In comparison, a cut-off of 10 kPa identified 10/11 of patients with HCC and had a sensitiv-
ity and specificity of 58.5% and 90.9% and a PPV and NPV of 2.2% and 99.7%.
Of the two patients who were diagnosed with HCC post treatment, the first was a female in
her mid-fifties with a pLSM of 4.7 kPa and no history of heavy alcohol use or diabetes while
the other was a male in his late fifties with a pLSM of 13.0 kPa and a history of both heavy alco-
hol use and diabetes.
In univariate analysis, older age (sHR 1.08 (95% CI 1.00–1.11), p<0.001), diabetes (sHR
4.64 (95% CI 1.39–15.4), p = 0.012) and a pLSM�17.5 kPa (sHR 11.2 (95% CI 2.42–52.3),
p = 0.002) was significantly associated with developing HCC post treatment (Table 4).
Table 1. Demographic characteristics for 773 patients with chronic hepatitis C treated with direct acting antivirals at baseline according to pretreatment liver stiff-
ness measurement.
<10 kPa 10–17.4 kPa 17.5–75 kPa P All
n = 321 (41.5%) n = 249 (32.2%) n = 203 (26.3%) n = 773
Median age, years (IQR) 50 (42–60) 55 (47–61) 56 (49–61) <0.001 54 (45–61)
Male sex, n (%) 185 (57.6) 171 (68.7) 136 (67.0) 0.013 492 (63.7)
Western origin, n (%) 276 (86.0) 204 (81.9) 171 (84.2) 0.420 651 (84.2)
Diabetes, n (%) 14 (4.4) 32 (12.9) 35 (17.2) <0.001 81 (10.5)
Heavy alcohol use, n (%) 141 (43.9) 129 (51.8) 126 (62.1) <0.001 396 (51.2)
Intravenous drug use, n (%) 201 (62.6) 153 (61.5) 134 (66.0) 0.588 488 (63.1)
Median ALAT at pLSM (IQR) 63 (39–102) 78 (46–134) 97 (57–145) <0.001 75 (44–125)
Median Follow-up, 32 (20–42) 36 (27–45) 42 (28–50) <0.001 36 (25–46)
months (IQR)
Abbreviations: SVR: sustained virological response, LSM: liver stiffness measurements, ALAT: alanine aminotransferase, pLSM: pretreatment liver stiffness measurement.
https://doi.org/10.1371/journal.pone.0243725.t001
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In multivariate analysis only increasing age (sHR 1.07 (95% CI 1.03–1.12), p<0.001) and
having a pLSM�17.5 kPa (HR 8.88 (95% CI 1.78–44.3), p = 0.003) was significantly associated
with incident HCC while the association with diabetes (sHR 2.82 (95% CI 0.81–9.81),
p = 0.103) did not reach statistical significance.
Decompensated cirrhosis and all-cause mortality
Compensated cirrhosis was seen in 14 patients (1.8%) during follow-up, with an overall rate of
0.6/100 PY (95% CI 0.4–1.1) while 38 patients died (4.9%) yielding an all-cause mortality rate
of 1.7/100 PY (95% CI 1.2–2.3/100 PY). The median follow-up for patients with incident
decompensated cirrhosis was 7 months (IQR 2–13) and 26 months (IQR 15–30) among
patients who died. The median pLSM was 38.8 kPa (IQR 26.3–56.1, range 12.3–70.6) among
patients who developed decompensated cirrhosis during the follow-up period and 27.1 kPa
(IQR 11.7–42.2, range 6.8–65.2) among patients who died.
Fig 2. Overall incidence of hepatocellular carcinoma for 773 patients achieving SVR after DAA treatment stratified by baseline LSM groups. Abbreviations; SVR;
sustained virological response, DAA; direct-acting antivirals, kPa; kilopascal, LSM; liver stiffness measurement.
https://doi.org/10.1371/journal.pone.0243725.g002
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During follow-up the median age at first episode of decompensated cirrhosis was 57 years
(IQR 50–63, range 43–64) and the median age at the time of death was 59 years (IQR 53–64,
range 40–67).
Table 2. Pretreatment LSM predicting decompensated cirrhosis, hepatocellular carcinoma and all-cause death during follow-up.
Cut-off (kPa) Patients >Cut-off (%) Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Hepatocellular carcinoma
Optimized cut-off 17.5 26.3 81.8 74.5 4.4 99.7
Cut-off for 90% sensitivity 4.8 92.0 90.0 8.0 1.4 98.2
Cut-off for 90% specificity 28.0 9.8 45.5 90.0 6.2 99.1
12.5 kPa 12.5 43.5 90.9 57.0 2.9 99.7
10 kPa 10.0 58.5 90.9 42.0 2.2 99.7
Decompensated cirrhosis
Optimized cut-off 26.3 12.8 78.6 87.8 10.6 99.6
Cut-off for 90% sensitivity 12.3 45.3 90.0 56.1 3.6 99.7
Cut-off for 90% specificity 28.0 9.8 64.3 90.0 10.5 99.2
17.5 kPa 17.5 26.3 78.6 74.7 5.4 99.5
12.5 kPa 12.5 43.5 92.9 57.2 3.8 99.8
10 kPa 10 58.5 100 42.3 3.1 100
All-cause death
Optimized cut-off 25.4 13.6 57.9 88.4 21.2 97.6
Cut-off for 90% sensitivity 6.9 71.9 90.0 27.6 6.0 98.2
Cut-off for 90% specificity 27.0 11.3 50.0 90.0 20.5 97.2
17.5 kPa 17.5 26.3 63.2 75.7 11.8 97.6
12.5 kPa 12.5 43.5 73.7 57.8 8.3 97.7
10 kPa 10 58.5 81.6 42.7 6.8 97.8
Abbreviations: kPa; kilopascal, PPV; positive predictive value, NPV; negative predictive value.
https://doi.org/10.1371/journal.pone.0243725.t002
Table 3. Incidence rates of cirrhosis decompensation, HCC and overall mortality according to pretreatment LSM for 773 patients with chronic hepatitis C treated
with direct acting antivirals.
n per Incidence per 100 person year Hazard ratio p
person-years (95% CI)
Hepatocellular carcinoma
LSM <10 kPa 1/851 0.12 (0.02–0.83) 1 (reference)
LSM 10–17.4 kPa 1/733 0.14 (0.02–0.97) 1.14 (0.07–18.3) 0.925
LSM 17.5–75 kPa 9/642 1.40 (0.73–2.70) 12.3 (1.55–97.1) 0.017
Decompensated cirrhosis
LSM < 10 kPa 0/851 0 (0–0.43)� NA
LSM 10–17.4 kPa 3/725 0.41 (0.13–1.30) NA 0.973
LSM 17.5–75 kPa 11/626 1.76 (1.0–3.17) NA <0.001
All-cause mortality
LSM < 10 kPa 7/851 0.82 (0.39–1.73) 1 (reference)
LSM 10–17.4 kPa 7/735 0.95 (0.45–2.0) 1.19 (0.41–3.40) 0.751
LSM 17.5–75 kPa 24/654 3.67 (2.46–5.47) 4.39 (1.88–10.2) 0.001
Abbreviations: LSM; Liver stiffness measurement, kPa; kilopascal, CI; confidence interval, NA; not analyzed due to zero events in the reference group.
� 0.975% CI.
https://doi.org/10.1371/journal.pone.0243725.t003
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There was no difference among patients with a pLSM of<10 kPa and 10–17.4 kPa in inci-
dence rates of decompensated cirrhosis (0/321 (0%), 0/100 PY vs 3/249 (1.2%), 0.41/100 PY,
p = 0.925) (Table 3, Fig 3) or in all-cause mortality rates (7/321 (2.18%), 0.82/100 PY vs 7/249
(2.81%) 0.95/100 PY, p = 0.751) (Table 3, Fig 4) but patients with a pLSM�17.5 kPa had a sig-
nificantly higher incidence rate of decompensated cirrhosis (11/203 (5.42%), 1.76/100 PY,
p<0.001) and all-cause mortality rate (24/203 (11.8%), 3.67/100 PY, p = 0.001).
Table 4. Factors associated with hepatocellular carcinoma, decompensated cirrhosis and all-cause mortality among 773 patients with chronic hepatitis C treated
with direct acting antivirals.
Hepatocellular carcinoma
Univariate Multivariate
Variable sHR (95% CI) p-value sHR (95% CI) p-value
Age, years 1.08 (1.00–1.11) <0.001 1.07 (1.03–1.12) <0.001
Male sex 1.00 (0.29–3.44) 0.992
Western European 0.83 (0.18–3.88) 0.813
ALAT at pLSM 1.00 (0.99–1.01) 0.556
Diabetes 4.64 (1.39–15.4) 0.012 2.82 (0.81–9.81) 0.103
Ever heavy alcohol use 2.49 (0.66–9.37) 0.178
Ever intravenous drug use 1.02 (0.30–3.50) 0.975
Days from pLSM to treatment 1.00 (1.00.1.01) 0.316
Pretreatment LSM�17.5 kPa 11.2 (2.42–52.5) 0.002 8.88 (1.78–44.3) 0.003
Delta LSM�0 1.86 (0.23–15.2) 0.560
Decompensated cirrhosis
Univariate Multivariate
Variable sHR (95% CI) p-value sHR (95% CI) p-value
Age, years 1.02 (0.98–1.06) 0.328
Male sex 7.54 (0.99–57.2) 0.051
Western European 1.12 (0.25–5.00) 0.882
ALAT at pLSM 0.99 (0.98–1.01) 0.297
Diabetes 1.42 (0.32–6.37) 0.649
Ever heavy alcohol use 3.52 (0.98–12.6) 0.053
Ever intravenous drug use 2.16 (0.60–7.72) 0.237
Days from pLSM to treatment 1.00 (1.00–1.01) 0.056
Pretreatment LSM�17.5 kPa 10.3 (2.87–36.7) <0.001 10.3 (2.87–36.7) <0.001
Delta LSM�0 5.17 (1.06–25.2) 0.042
All-cause mortality
Univariate Multivariate
Variable HR (95% CI) p-value HR (95% CI) p-value
Age, years 1.03 (0.99–1.07) 0.056
Male sex 1.60 (0.78–3.29) 0.203
Western European 1.53 (0.54–4.30) 0.425
ALAT at pLSM 0.99 (0.98–1.00) 0.052
Diabetes 3.84 (1.94–7.61) <0.001 3.01 (1.50–6.04) 0.002
Ever heavy alcohol use 1.75 (0.90–3.43) 0.100
Ever intravenous drug use 1.29 (0.65–2.56) 0.464
Days from pLSM to treatment 1.00 (0.99–1.01) 0.483
Pretreatment LSM�17.5 kPa 4.05 (2.09–7.85) <0.001 3.52 (1.80–6.90) <0.001
Delta LSM�0 0.91 (0.12–6.87) 0.928
Abbreviations: HR; hazard ratio, LSM; liver stiffness measurement, kPa; kilopascal.
https://doi.org/10.1371/journal.pone.0243725.t004
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The optimized cut-off for decompensated cirrhosis was 26.3 kPa, which identified 11/14
patients with incident decompensated cirrhosis with NPV of 99.7%, while the optimized cut-
off for all-cause mortality was 25.4 kPa, which identified 22/38 of patients who died during the
follow-up and NPV of 97.6% (Table 2).
A cut-off of 17.5 kPa identified 11/14 of patients with decompensated cirrhosis with NPV
99.5%, while it identified 24/38 of patients who died of all causes during follow-up with NPV
of 97.6% (Table 2).
In univariate analysis, a pLSM�17.5 kPa (sHR 10.3 (95% CI 2.87–36.7)), p<0.001) and a
dLSM�0 (sHR 5.17 (95% CI 1.06–25.2)) was significantly associated with decompensated cir-
rhosis (Table 4).
All-cause mortality was significantly associated with diabetes in both univariate (HR 3.84
(95% CI 1.44–5.78, p<0.001) and multivariate analysis (HR 3.01 (95% CI 1.50–6.04) p = 0.002)
and with having a pLSM�17.5 kPa in univariate (HR 4.05 (95% CI 2.09–7.85), p<0.001) and
multivariate analysis (HR 3.52 (95% CI 1.80–6.90), p<0.001) (Table 4).
Fig 3. Overall incidence of decompensated cirrhosis for 773 patients achieving SVR after DAA treatment stratified by baseline LSM groups.
Abbreviations; SVR; sustained virological response, DAA; direct-acting antivirals, kPa; kilopascal, LSM; liver stiffness measurement.
https://doi.org/10.1371/journal.pone.0243725.g003
PLOS ONE Incidence of HCC in chronic hepatitis C patients who achieve SVR following DAAs
PLOS ONE | https://doi.org/10.1371/journal.pone.0243725 December 10, 2020 11 / 17
Discussion
The findings of this Danish nationwide cohort study showed that pLSM has a prognostic value
for the development of HCC, decompensated cirrhosis, and overall survival in CHC patients
achieving SVR after DAA therapy. We found a cut-off of 17.5 kPa to be a good predictor of
incident HCC with incidence rates increasing 10-fold above this cut-off compared to patients
with a pLSM below 17.5 kPa. We did not find a significantly higher risk of developing HCC in
patients with a pLSM of 10–17.4 kPa compared to patients with a pLSM <10 kPa. This was
unexpected and may have been due to the low number of patients with HCC in our study or
the length of the follow-up. The one patient with a pLSM of 10–17.4 kPa who developed HCC
during follow-up had multiple known risk factors for HCC in the form of older age, male sex,
alcohol abuse and diabetes. As the negative predictive value for the cut-off of 17.5 kPa was very
high at 99.7%, this could suggest that within the first three years after cure for hepatitis C,
monoinfected patients with no prior episode of HCC or decompensated cirrhosis and with a
pretreatment LSM below 17.5 kPa may not benefit from HCC surveillance. However, patients
Fig 4. Overall survival for 773 patients achieving SVR after DAA treatment stratified by baseline LSM group. Abbreviations; SVR; sustained virological response,
DAA; direct-acting antivirals, kPa; kilopascal, LSM; liver stiffness measurement.
https://doi.org/10.1371/journal.pone.0243725.g004
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with a pLSM of 10–17.4 kPa and other risk factors for HCC should also be considered for
HCC screening, based on individual risk assessment.
Our findings are in line with recent study by Shiha et al. [31] that followed 2372 patients
monoinfected with HCV with no prior episodes of decompensated cirrhosis or HCC who
achieved SVR after treatment with DAA for an average of 23.6 months. In 638 patients with a
pretreatment LSM of 10.3–16.3 kPa Shiba et al. found a HCC incidence rate of 0.664/100 PY
compared to 2.917/100 PY among 1734 patients with a pretreatment LSM of�16.4 kPa.
Also, in a study including 572 CHC patients treated with DAA and pretreatment LSM�10
kPa and no prior episodes of decompensated cirrhosis of HCC, Pons et al. [16] found a greater
proportion of patients who developed HCC among patients with a pretreatment LSM of�20
kPa compared to 10–19.9 kPa (6.1% (13/212) vs 3.6% (12/360), p = 0.114) during a median fol-
low-up of 2.8 years. Among the five patients in the study who developed decompensated cir-
rhosis, all had a pretreatment LSM�20 kPa.
Similarly, Hansen et al. [32] followed 591 patients with chronic hepatitis C for a median of
46.1 months and found that cirrhotic complications, defined as first episode of HCC or
decompensated cirrhosis, occurred almost exclusively in patients with a baseline LSM of 17
kPa, with a negative predictive value of 98.0%.
A recent paper estimated that biannual screening for HCC in patients with SVR after treat-
ment for CHC would be cost effective in patients with an HCC incidence of�1.32% per year
with an incremental cost-effectiveness ratio (ICER)< $50,000/quality adjusted life-year
(QALY) [33]. Also, apart from cost effectiveness, screening patients with low incidence rates
increases the risk of having a false positive ultrasound-based HCC diagnosis [33, 34], which
leads to additional tests, in some cases including biopsy, perhaps therapy and the anxiety of a
cancer diagnosis [35]. The results from our study, as well as the study by Shiha et al. [31], sug-
gest that patients with a pLSM of<17.5 kPa can be safely omitted from post treatment HCC
screening. However further studies are needed to clarify if this holds true during prolonged
and longer follow-up.
A drop in LSM after treatment was associated with a reduction in incident decompensated
cirrhosis but not incident HCC or overall-death. A recent study by Pons et al. of CHC patients,
treated with DAA and pLSM�10 kPa, also showed no statistically significant association
between having a decrease of�20% in LSM at one-year follow-up after treatment and reduc-
tion in HCC incidence [16]. Conversely, Ravaioli et al. found that a reduction in LSM of>30%
from baseline to end of treatment with DAA for CHC was inversely associated with develop-
ment of HCC in a smaller, retrospective study with 139 patients with Child-Pugh A and B cir-
rhosis [19].
The low number of incident HCC among patients with a follow-up LSM in our study
would make it difficult to show a difference in outcome among the groups with delta LSM�0
and<0, respectively.
This study has several limitations. We derived our data retrospectively from registers which
might be expected to result in less accurate ascertainment of exposures and outcomes than a
prospective follow-up. Secondly, the pLSM was not performed on the date of treatment initia-
tion in most patients and could have changed in either direction in the intervening time [36].
However, in most of the patients, the pLSM was performed less than six months before treat-
ment initiation and time from pLSM to index date was not significantly associated with out-
comes in the regression analyses. Thirdly, we did not have data on whether pLSM were
performed with the patients fasting. As LSM can be falsely elevated if the patient is not fasting
[37] this could have caused an overestimation of the LSM cutoffs in the study.
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However, patients in Denmark are instructed to be fasting when having LSM performed
and as almost all patients had at least one LSM prior to the pLSM, most would be expected to
have been fasting at the time of the pLSM.
Also, the follow-up time in our study was rather short (36 months). However, a recent
study by Iounnaou et al. [4] showed that the elevated risk of HCC after SVR in cirrhotic
patients treated for CHC with interferon based or interferon free therapy did not increase dur-
ing a follow-up of up to 10 years, but further long-term studies are needed to confirm this.
It would have been a great advantage to the study if serological markers of liver fibrosis,
such as FIB-4, had been available to corroborate our LSM findings, but as aspartate amino-
transferase (AST) was not a standard test in Denmark during the study period, and only avail-
able for a small proportion of patients.
It would have been preferable to also have LSM at end of treatment (EOT) or at SVR as the
inflammation caused by CHC can cause an elevation of LSM, regardless of fibrosis and LSM at
SVR could be more accurate at predicting outcomes after DAA treatment [38]. However, LSM
at EOT or SVR was not available in most patients. Furthermore, a significant part of patients
in treatment for CHC are lost to follow up, especially vulnerable patients like those with active
injecting drug use or suffering from homelessness [39]. Being able to provide prognostication
and reassurance at the time of treatment initiation would be important, especially in patients
at risk of lost to follow up after treatment.
Conclusions
In conclusion, our study suggests that pLSM can be used to risk stratify CHC patients with no
previous episode of decompensated cirrhosis or HCC who achieve SVR after treatment with
DAAs. Patients in this group with a pretreatment LSM below 17.5 kPa without other risk fac-
tors for cirrhosis and HCC appear not to benefit from HCC surveillance within the first 3
years of cure. However, further longtime follow-up studies are needed to confirm our findings
and to address whether HCC screening can be avoided hereafter.
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at the time of sustained virological response predicts the clinical outcome in HIV/HCV-coinfected
patients with advanced fibrosis treated with direct-acting antivirals. Clinical infectious diseases: an offi-
cial publication of the Infectious Diseases Society of America. 2019. Epub 2019/11/23. https://doi.org/
10.1093/cid/ciz1140 PMID: 31754695.
39. Nouch S, Gallagher L, Erickson M, Elbaharia R, Zhang W, Wang L, et al. Factors associated with lost to
follow-up after hepatitis C treatment delivered by primary care teams in an inner-city multi-site program,
Vancouver, Canada. The International journal on drug policy. 2018; 59:76–84. Epub 2018/07/27.
https://doi.org/10.1016/j.drugpo.2018.06.019 PMID: 30048877.
PLOS ONE Incidence of HCC in chronic hepatitis C patients who achieve SVR following DAAs
PLOS ONE | https://doi.org/10.1371/journal.pone.0243725 December 10, 2020 17 / 17
